Atai life sciences announces results from phase 2a trial of pcn-101 (r-ketamine) for treatment-resistant depression

New york and berlin, jan. 06, 2023 (globe newswire) -- atai life sciences (nasdaq: atai) (“atai” or “the company”), a clinical-stage biopharmaceutical company focused on mental health, announced that, while pcn-101 (r-ketamine) demonstrated signals of efficacy across all timepoints out to two weeks, perception neuroscience's phase 2a clinical trial did not meet its primary endpoint of a statistically significant change from baseline in participants' madrs (montgomery-åsberg depression rating scale) score at 24 hours compared to placebo.
ATAI Ratings Summary
ATAI Quant Ranking